Opinions
Jim Cramer - Mad Money
Sarepta Therapeutics
SRPT-Q
DON'T BUY
Jan 15, 2025
$119.430
Stock price when the opinion was issued
biotechnology
pharmaceutical
It's the ideal tool to help you make quicker, more informed decisions for
managing and tracking your investments.
The RNA-based therapeutic companies are not doing well. Maybe it's a reverse-halo effect of the Moderna report. It's troubling.